Study | Nation | Study design | Study period | Sample size, n | Mean age (year) | Male, % | CHT, n | EBRT, n | Tumor Size (mean, cm) | Median Survival Time (month) | Tumor Staging, n (+) vs. (−) | Study quality | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
(+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | (+) | (−) | ||||||
Dobelbower-1 1997 [14] | USA | R | 1980–1995 | 10 | 14 | 58.4 | 60.5 | 54.5%a | 9 | 9 | 10 | 14 | 4.8 | 3.3 | 17.5 | 14.5 | Stage I: 1 vs. 4 Stage II: 4 vs, 6 Stage III: 6 vs. 4 | ******* | |
Nishimura 1997 [28] | Japan | R | 1980–1995 | 32 | 24 | 62a | NA | NA | 6 | 2 | 19 | 24 | NA | NA | 15.5 | 13.0 | Stage I: 13% vs. 8% Stage II: 13% vs. 29% Stage III: 48% vs. 39% Stage IV: 28% vs. 24% | ****** | |
Reni 2001 [10] | Italy | R | 1985–1998 | 127 | 76 | 61.8 | 62.3 | 52 | 63.2 | 56 | 26 | 41 | 15 | 3.2 | 3.5 | 14.5 | 12.0 | Stage I: 5 vs. 4 Stage II: 25 vs, 15 Stage III: 55 vs. 35 Stage IV: 42 vs. 22 | ******* |
Showalter 2009 [25] | USA | PCD | 1995–2005 | 37 | 46 | 64 | 67 | NA | NA | 26 | 27 | 23 | 29 | NA | NA | 19.2 | 21.0 | Stage I: 7 vs. 16 Stage IIA: 6 vs. 12 Stage ≥IIB: 24 vs. 18 | ****** |
Calvo 2013 [22] | Spain | PCD | 1995–2012 | 29 | 31 | 60 | 62 | 58.6 | 64.5 | 18 | 19 | 29 | 31 | NA | NA | NA | NA | Stage IB-IIA: 13 vs. 16 Stage IIB-III: 16 vs. 15 | ******* |
Keane 2018 [29] | USA | R | 2010- 2015 | 22 | 19 | 63a | 37a | 22 | 19 | 22 | 19 | 3.6a | 35.1 | 24.5 | 41 underwent resection (no evidence of distant metastases after NAT) | ******* |